Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease

NCT07656142 · tracked via the Priya Life Science China tracker
Sponsor
Tiantian Li
Phase
Not applicable
Started
2026-08-04
Last updated
2026-10-23

Condition(s) studied

Chronic Obstructive Pulmonary Disease

Investigational drug(s) / intervention(s)

Mobile Application-Based Personalized Temperature Health Risk Early Warning Intervention

Mobile Application-Based Personalized Temperature Health Risk Early Warning Intervention: This study implements a digital early warning intervention targeting personalized temperature-related health risks. The mobile application integrates real-time meteorological data and individual characteristics to generate risk levels and deliver tailored health alerts and guidance aimed at supporting risk management and reducing exposure-related health risks.

Study summary

This study will test whether a personalized mobile application that provides temperature-related health risk warnings and protective recommendations can reduce acute exacerbations in people with chronic obstructive pulmonary disease (COPD). Researchers will compare participants who receive the mobile application in addition to usual care with those who receive usual care alone. The main question is whether the mobile application reduces the number of COPD acute exacerbation events over 12 months. The study will also evaluate secondary outcomes including quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature risk perception, and participants' use of the mobile application.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Hospital inclusion criteria: 1. Tertiary hospitals; 2. Hospitals with respiratory wards that admit patients with COPD; 3. Hospitals with a well-established electronic health record system and follow-up capability; 4. Hospitals able to assign a study coordinator. Patient inclusion criteria: 1. Age \>=40 years and \<=80 years, with no restriction on sex; 2. Patients with stable chronic obstructive pulmonary disease; 3. At least 1 severe acute exacerbation requiring hospitalization, or at least 2 moderate acute exacerbations requiring outpatient or emergency care, within the previous year; 4. Local permanent residents with a duration of residence \>=6 months; 5. Patients who voluntarily agree to participate, are expected to have good adherence, are able to sign informed consent; 6. Patients who own a smartphone or other smart device. Hospital exclusion criteria: 1. Primary hospitals or private hospitals; 2. Hospitals unable to cooperate with the study protocol. Patient exclusion criteria: 1. Patients with asthma; 2. Women who are known to be pregnant or breastfeeding, or who have a positive pregnancy test before cluster randomization; 3. Patients with other diseases that may affect participation in the trial, such as refractory hypertension or severe aphasia; 4. Patients currently receiving psychiatric or psychological treatment that may contaminate study results; 5. Expected survival time \<1 year, such as in those with malignant tumors or severe cardiopulmonary disease; 6. Participation in other interventional clinical studies that may affect outcome assessment; 7. Any other circumstances in which the investigator considers the patient unsuitable for participation in this study or at significant risk, such as cognitive impairment preventing understanding of and/or compliance with study procedures and/or follow-up.

Primary outcome measure(s)

  • Number of COPD Acute Exacerbations — 12 months after baseline
    Total number of acute exacerbations of COPD managed at home, via outpatient visits, emergency department visits, or hospitalizations.

Trial sites (4)

FacilityCityRegionStatus
Beijing Anzhen Hospital, Capital Medical University Beijing China Recruiting
Beijing Huairou Hospital Beijing China Recruiting
Civil Aviation General Hospital Beijing China Recruiting
Emergency General Hospital Beijing China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07656142 on ClinicalTrials.gov ↗ ← All trials in China